CUSIP: 89620X506
Q1 2020 13F Holders as of 31 Mar 2020
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
60,530,436
-
Share change
-
+45,184,926
-
Total reported value
-
$244,211,456
-
Put/Call ratio
-
40%
-
Price per share
-
$4.04
-
Number of holders
-
65
-
Value change
-
+$185,667,444
-
Number of buys
-
55
-
Number of sells
-
8
Institutional Holders of TRILLIUM THERAPEUTICS INC - COM NEW as of Q1 2020
As of 31 Mar 2020,
TRILLIUM THERAPEUTICS INC - COM NEW was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
60,530,436 shares.
The largest 10 holders included
VR Adviser, LLC, RA CAPITAL MANAGEMENT, L.P., NEA Management Company, LLC, Avoro Capital Advisors LLC, BOXER CAPITAL, LLC, CITADEL ADVISORS LLC, Marshall Wace North America L.P., DEUTSCHE BANK AG\, FRAZIER MANAGEMENT LLC, and ALLIANCEBERNSTEIN L.P..
This page lists
65
institutional shareholders reporting positions in this security
for the Q1 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.